phase-3 asthma promise clashes with post-IPO speculation.
Generate Biomedicines’ clinical AI-medicine pipeline is promising, but the setup feels too speculative for new adds.
Generate Biomedicines is using generative biology to design programmable protein therapeutics, with its GB0895 asthma program in phase three. Still, it’s a cash-burning clinical-stage biotech with a volatile post-IPO stock, so the risk profile makes it a pass for investors adding here.
"3 New AI Stocks NVIDIA is Buying Now! 😮"